Lung tumors near the trachea, large bronchi or esophagus are often treated with radiotherapy. The special thing about your lung tumor is its "ultra-central" location near radiation-sensitive structures such as the trachea, large bronchi and esophagus. There may be an increased risk of severe side effects. For this reason, lung tumors in an "ultracentral" location are treated with a reduced radiation dose. Unfortunately, reducing the radiation dose also limits the effectiveness of radiotherapy. Using a new, already approved hybrid radiation device, the MRI Linac, the position of the tumor can be monitored during radiation with MRI images. MRI monitoring allows the radiation dose to be directed more precisely at the tumor, which means that the surrounding tissue can be better protected. This protection of the surrounding tissue enables us to treat lung tumors like yours with higher radiation doses in this study.
Aim of the study
The aim of this study is to determine the optimal radiation dose for MRI-guided radiotherapy of lung tumors near radiosensitive structures such as the trachea, large bronchi and esophagus. In other words, we want to determine the most effective radiation dose with the best possible tolerability.
Who can take part?
Patients with lung tumors in an ultracentral location (close to radiosensitive structures such as trachea, bronchi, esophagus)
Procedure
Most of the measures and examinations planned in the course of the study are also part of the MRI-guided radiotherapy of "ultracentral" lung tumors without participation in the study. Depending on the current status of the study, you may be treated with a higher radiation dose. An irradiation session including MRI imaging takes between 20 and 40 minutes. Study participants fill out additional questionnaires at the appointments. Study participation ends after 10 appointments, approximately 2 years and 6 weeks after the study treatment. If you give your consent, an additional evaluation of the longer-term course can be carried out, even after the end of the follow-up phase.
Compensation
If you participate in this study, you will not receive any money or other compensation.
Original study name
Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location (MAGELLAN trial)
BASEC number
2023-01297
Sponsors